Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro

Journal of Psychiatric Research

Volumn 47, Issue 11, 2013, Pages 1751-1759

  Himmerich, Hubertus ^a   Bartsch, Stefanie ^a   Hamer, Hajo ^b   Mergl, Roland ^a   Schönherr, Jeremias ^a   Petersein, Charlotte ^a   Munzer, Alexander ^a   Kirkby, Kenneth Clifford ^c   Bauer, Katrin ^a   Sack, Ulrich ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Antiepileptic drugs; Bipolar disorder; Cytokines; Epilepsy; Mood stabilizer

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOKINE; ETIRACETAM; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OXCARBAZEPINE; PHENOBARBITAL; PRIMIDONE; TOPIRAMATE; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ANTIEPILEPTIC DRUGS; BIPOLAR DISORDER; CYTOKINES; EPILEPSY; MOOD STABILIZER;

ADULT; ANTICONVULSANTS; ANTIEMETICS; BLOOD CELLS; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84884418295     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.07.026     Document Type: Article

References (81)

1. Andrzejczak D. Epilepsy and pro-inflammatory cytokines. Immunomodulating properties of antiepileptic drugs. Neurologia i Neurochirurgia Polska 2011, 45:275-285.
2. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased invitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry 2000, 5:150-158.
3. Basta-Kaim A., Budziszewska B., Lasoń W. Effects of antiepileptic drugs on immune system. Przegla̧d Lekarski 2008, 65:799-802.
4. Bhat R., Axtell R., Mitra A., Miranda M., Lock C., Tsien R.W., et al. Inhibitory role for GABA in autoimmune inflammation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2580-2585.
5. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. Pharmacopsychiatry 2004, 37:243-265.
6. Bjurstöm H., Wang J., Ericsson I., Bengtsson M., Liu Y., Kumar-Mendu S., et al. Anatural immunomodulator of T lymphocytes. Journal of Neuroimmunology 2008, 205:44-50.
7. Black J.A., Newcombe J., Waxman S.G. Nav1.5 sodium channels in macrophages in multiple sclerosis lesions. Multiple Sclerosis 2013, 19:532-542.
8. Carrithers L.M., Hulseberg P., Sandor M., Carrithers M.D. The human macrophage sodium channel NaV1.5 regulates mycobacteria processing through organelle polarization and localized calcium oscillations. FEMS Immunology and Medical Microbiology 2011, 63:319-327.
9. Costa M.M., Pereiro P., Wang T., Secombes C.J., Figueras A., Novoa B. Characterization and gene expression analysis of the two main Th17 cytokines (IL-17A/F and IL-22) in turbot, Scophthalmus maximus. Developmental and Comparative Immunology 2012, 38:505-516.
10. De Sarro G., Rotiroti D., Audino M.G., Gratteri S., Nisticò G. Effects of interleukin-2 on various models of experimental epilepsy in DBA/2 mice. Neuroimmunomodulation 1994, 1:361-369.
11. Dinges M.M., Orwin P.M., Schlievert P.M. Exotoxins of Staphylococcus aureus. Clinical Microbiology Reviews 2000, 13:16-34.
12. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L.V., Beumer W., Versnel M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics 2010, 10:59-76.
13. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behaviour and Immunity 2006, 20:532-545.
14. Dubé C.M., Brewster A.L., Baram T.Z. Febrile seizures: mechanisms and relationship to epilepsy. Brain & Development 2009, 31:366-371.
15. El-Masri H.A., Portier C.J. Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide inhumans, rats, and mice. Drug Metabolism and Disposition 1998, 26:585-594.
16. Feske S., Skolnik E.Y., Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nature Reviews Immunology 2012, 12:532-547.
17. + channel activity. FEBS Letters 2004, 569:191-194.
18. Granger P., Biton B., Faure C., Vige X., Depoortere H., Graham D., et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995, 47:1189-1196.
19. Grunze H., Walden J. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. Journal of Affective Disorders 2002, 72(Suppl.1):15-21.
20. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J., et al. WFSBP task force on treatment guidelines for bipolar disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry 2013, 14:154-219.
21. Hegerl U., Himmerich H., Engmann B., Hensch T. Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment?. Current Opinion in Psychiatry 2010, 23:1-7.
22. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmunity Reviews 2010, 9:785-792.
23. Himmerich H., Koethe D., Schuld A., Yassouridis A., Pollmächer T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl) 2005, 179:447-451.
24. Himmerich H., Kaufmann C., Schuld A., Pollmächer T. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. Journal of Psychiatric Research 2005, 39:35-42.
25. Himmerich H., Beitinger P.A., Fulda S., Wehrle R., Linseisen J., Wolfram G., et al. Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Archives of Internal Medicine 2006, 166:1739-1743.
26. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., et al. Depression, comorbidities and the TNF-alpha system. European Psychiatry 2008, 23:421-429.
27. Himmerich H., Berthold-Losleben M., Pollmächer T. The relevance of the TNF-alpha system in psychiatric disorders. Fortschritte der Neurologie-Psychiatrie 2009, 77:334-345.
28. Himmerich H., Fulda S., Sheldrick A.J., Blümäkers B., Rink L. Interferon-γ reduction by tricyclic antidepressants. International Journal of Psychiatry in Medicine 2010, 40:413-424.
29. Himmerich H., Schönherr J., Fulda S., Sheldrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. Journal of Psychiatric Research 2011, 45:1358-1365.
30. Himmerich H., Sorge S., Kirkby K.C., Steinberg H. Schizophrenic disorders. The development of immunological concepts and therapy in psychiatry. Nervenarzt 2012, 83:7-15.
31. Hinze-Selch D., Pollmächer T. Invitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain, Behavior and Immunity 2001, 15:282-318.
32. Hope S., Dieset I., Agartz I., Steen N.E., Ueland T., Melle I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. Journal of Psychiatric Research 2011, 45:1608-1616.
33. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scandinavian Journal of Immunology 2011, 74:1-13.
34. Kim J.E., Choi H.C., Song H.K., Jo S.M., Kim D.S., Choi S.Y., et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neuroscience Letters 2010, 471:94-99.
35. Kirchner H., Kleinicke C., Digel W. Awhole-blood technique for testing production of human interferon by leukocytes. Journal of Immunological Methods 1982, 48:213-219.
36. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C., Akkerhuis G.W., et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disorders 2007, 9:743-753.
37. Koçer A., Memişoǧullari R., Domaç F.M., Ilhan A., Koçer E., Okuyucu S., et al. IL-6 levels in migraine patients receiving topiramate. Pain Practice 2009, 9:375-379.
38. Krause D.L., Riedel M., Müller N., Weidinger E., Schwarz M.J., Myint A.M. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated invitro blood culture from depressed patients. Inflammopharmacology 2012, 20:169-176.
39. Kum W.W., Laupland K.B., See R.H., Chow A.W. Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. Journal of Clinical Microbiology 1993, 31:2654-2660.
40. Li G., Bauer S., Nowak M., Norwood B., Tackenberg B., Rosenow F., et al. Cytokines and epilepsy. Seizure 2011, 20:249-256.
41. Li S., Yu M., Li H., Zhang H., Jiang Y. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome. Mediators of Inflammation 2012, 2012:260473.
42. Lo W.L., Donermeyer D.L., Allen P.M. Avoltage-gated sodium channel is essential for the positive selection of CD4(+) T cells. Nature Immunology 2012, 13:880-887.
43. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9861-9866.
44. MacDonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 1995, 36(Suppl.2):2-12.
45. Maes M., Song C., Lin A.H., Pioli R., Kenis G., Kubera M., et al. Invitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl) 1999, 143:401-407.
46. Mendu S.K., Bhandage A., Jin Z., Birnir B. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. PLoS One 2012, 7:e42959.
47. Micusan V.V., Desrosiers M., Gosselin J., Mercier G., Oth D., Bhatti A.R., et al. Stimulation of T cells and induction of interferon by toxic shock syndrome toxin 1. Reviews of Infectious Diseases 1989, 11(Suppl.1):305-312.
48. Müller N., Myint A.M., Schwarz M.J. Inflammation in schizophrenia. Advances in Protein Chemistry and Structural Biology 2012, 88:49-68.
49. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal of Affective Disorders 2013, 144:16-27.
50. Murdaca G., Colombo B.M., Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Internal and Emergency Medicine 2011, 6:487-495.
51. Nelson B.H. IL-2, regulatory T cells, and tolerance. Journal of Immunology 2004, 172:3983-3988.
52. Neuman M.G., Cohen L., Nanau R.M., Hwang P.A. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Translational Research 2012, 159:397-406.
53. Nisticò G., De Sarro G. Is interleukin 2 a neuromodulator in the brain?. Trends in Neurosciences 1991, 14:146-150.
54. Nowak M., Bauer S., Haag A., Cepok S., Todorova-Rudolph A., Tackenberg B., et al. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain, Behavior and Immunity 2011, 25:423-428.
55. Nylander A., Hafler D.A. Multiple sclerosis. The Journal of Clinical Investigation 2012, 122:1180-1188.
56. Pan H.F., Li X.P., Zheng S.G., Ye D.Q. Emerging role of interleukin-22 in autoimmune diseases. Cytokine & Growth Factor Reviews 2013, 24:51-57.
57. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. Adistinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology 2005, 6:1133-1141.
58. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
59. Rao R.S., Prakash A., Medhi B. Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research. Indian Journal of Experimental Biology 2009, 47:625-634.
60. Rho J.M., Donevan S.D., Rogawski M.A. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. The Journal of Physiology 1996, 497:509-522.
61. Robert V., Triffaux E., Savignac M., Pelletier L. Singularities of calcium signaling in effector T-lymphocytes. Biochimica et Biophysica Acta 2013, 1833:1595-1602.
62. Rubio-Perez J.M., Morillas-Ruiz J.M. Areview: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal 2012, 2012:756357.
63. Rzewuska M. Valproate in the treatment of bipolar disorder. Psychiatria Polska 2002, 36:239-257.
64. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scandinavian Journal of Immunology 1995, 41:534-538.
65. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clinical Immunology and Immunopathology 1996, 78:83-85.
66. 2+ regulates T-cell receptor activation by modulating the charge property of lipids. Nature 2013, 493:111-115.
67. Stertz L., Magalhães P.V., Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry 2013, 26:19-26.
68. St. Louis E.K. Monitoring antiepileptic drugs: a level-headed approach. Current Neuropharmacology 2009, 7:115-119.
69. Tian J., Chau C., Hales T.G., Kaufman D.L. GABA(A) receptors mediate inhibition of T cell responses. Journal of Neuroimmunology 1999, 96:21-28.
70. Tian J., Lu Y., Zhang H., Chau C.H., Dang H.N., Kaufman D.L. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. Journal of Immunology 2004, 173:5298-5304.
71. Tufekci K.U., Meuwissen R., Genc S., Genc K. Inflammation in Parkinson's disease. Advances in Protein Chemistry and Structural Biology 2012, 88:69-132.
72. Vezzani A., Moneta D., Richichi C., Aliprandi M., Burrows S.J., Ravizza T., et al. Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002, 43:30-35.
73. Vezzani A., Balosso S., Maroso M., Zardoni D., Noé F., Ravizza T. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Current Opinion in Investigational Drugs 2010, 11:43-50.
74. Vaughn B.V., Ali I. Sleep and epilepsy: opportunities for diagnosis and treatment. Neurologic Clinics 2012, 30:1249-1274.
75. 2+ channels through an intracellular pathway. Molecular Pharmacology 2012, 82:199-208.
76. Wang P., Bai F., Zenewicz L.A., Dai J., Gate D., Cheng G., et al. IL-22 signaling contributes to West Nile encephalitis pathogenesis. PLoS One 2012, 7:e44153.
77. Weschenfelder J., Sander C., Kluge M., Kirkby K.C., Himmerich H. The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatria Danubina 2012, 24:112-126.
78. White H.S. Mechanism of action of newer anticonvulsants. Journal of Clinical Psychiatry 2003, 64(Suppl.8):5-8.
79. Wittchen H.U., Zaudig M., Fydrich T. Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe 1997.
80. Yang K.D., Liou W.Y., Lee C.S., Chu M.L., Shaio M.F. Effects of phenobarbital on leukocyte activation: membrane potential, actin polymerization, chemotaxis, respiratory burst, cytokine production, and lymphocyte proliferation. Journal of Leukocyte Biology 1992, 52:151-156.
81. Zhu Z.F., Wang Q.G., Han B.J., William C.P. Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Research Bulletin 2010, 83:272-277.